Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dapsone
Drug ID BADD_D00580
Description A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
Indications and Usage For the treatment and management of leprosy and dermatitis herpetiformis.
Marketing Status approved; investigational
ATC Code D10AX05; J04BA02
DrugBank ID DB00250
KEGG ID D00592
MeSH ID D003622
PubChem ID 2955
TTD Drug ID D0MA9N
NDC Product Code 0023-5206; 29967-0007; 16110-526; 49938-102; 51672-4197; 68308-342; 51927-0085; 53596-014; 13668-605; 70954-135; 0713-0886; 16714-956; 51552-1042; 29033-036; 49938-101; 60429-495; 0378-4830; 14474-038; 50218-008; 51927-0083; 73309-094; 51672-1387; 71052-100; 72375-0006; 16110-367; 29033-037; 43353-222; 51672-1388; 60429-496; 60758-670; 70954-136; 10695-047; 51927-0084; 51672-4198; 46438-0645; 49452-2439; 65571-0021; 76072-1018; 64980-566; 14474-026; 45562-1120; 51927-4368; 58159-033; 43353-223; 0023-3670
UNII 8W5C518302
Synonyms Dapsone | DADPS | Sulfonyldianiline | Diaminodiphenylsulfone | Diaphenylsulfone | 4,4'-Diaminophenyl Sulfone | 4,4' Diaminophenyl Sulfone | Sulfone, 4,4'-Diaminophenyl | Sulfona | Dapson-Fatol | Disulone | Avlosulfone | Dapsoderm-X
Chemical Information
Molecular Formula C12H12N2O2S
CAS Registry Number 80-08-0
SMILES C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.0010.007810%-
Rash erythematous23.03.13.0290.002053%-
Rash maculo-papular23.03.13.0040.001100%
Renal failure20.01.03.0050.001100%-
Renal papillary necrosis05.07.02.001; 14.07.02.001; 20.01.07.002---
Respiratory distress22.02.01.0120.000733%-
Respiratory failure14.01.04.003; 22.02.06.0020.001833%
Reticulocyte count increased13.01.05.010---
Rosacea23.02.08.0010.000807%-
Shock24.06.02.0020.000367%-
Sinusitis11.01.13.005; 22.07.03.007--
Skin discolouration23.03.03.0050.003850%-
Skin disorder23.03.03.0070.000990%-
Skin exfoliation23.03.07.0030.008286%-
Skin hyperpigmentation23.05.01.0030.000367%
Skin irritation23.03.04.0090.003117%-
Skin lesion23.03.03.0100.000367%-
Skin necrosis23.03.03.0110.000550%-
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.0070.000550%
Suicide attempt19.12.01.0040.000917%
Supraventricular tachycardia02.03.03.0120.000367%
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.0180.002420%-
Tachycardia02.03.02.0070.001100%-
Tachypnoea22.02.01.0140.000367%-
Therapeutic response decreased08.06.01.0160.002493%-
Thrombocytopenia01.08.01.0020.000917%-
Thyroiditis05.02.04.0010.000550%-
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.0080.000917%
Type I hypersensitivity10.01.03.0060.000367%-
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene